WebJan 28, 2024 · GUANGZHOU, China-- ( BUSINESS WIRE )--Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceutical company, today announced that the … Web3 hours ago · Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular and eye diseases, and other severe and emerging unmet medical needs, as well as biosimilars for existing, …

Bio-Thera Solutions Announces BAT1006 Poster Presentations at …

Web3 hours ago · Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced the company will present one poster concerning Phase 1 … WebNov 1, 2024 · GUANGZHOU, China--(BUSINESS WIRE)-- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase III clinical study for BAT2306, a proposed biosimilar of Cosentyx ® (secukinumab).The clinical study is a randomized, double-blind, parallel group, active … crypto miner etf

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a ...

WebApr 13, 2024 · Bio-Thera Solutions, Ltd. is a China-based company mainly engaged in the research and development of innovative drugs and biosimilars. The Company is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life … WebAug 27, 2024 · Bio-Thera is eligible for an upfront payment of $20 million as well as further development and commercial milestones of up to $130 million. “Partnering with Hikma to commercialize BAT2206, our ustekinumab biosimilar, further validates the high quality of the work performed at Bio-Thera,” said Dr. Shengfeng Li, CEO of Bio-Thera Solutions. WebMar 13, 2024 · Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular and eye diseases, and other severe and emerging unmet medical needs, as well as biosimilars for existing, … crypto miner financing